je.st
news
Merck Statement on FDA Advisory Committee for Vorapaxar, Mercks Investigational Antiplatelet Medicine
2014-01-16 00:59:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)s Cardiovascular and Renal Drugs Advisory Committees recommendation for approval of vorapaxar. Vorapaxar is the companys investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
medicine
committee
advisory
Category:Biotechnology and Pharmaceuticals